



SHIONOGI Science Program

 **SHIONOGI & CO., LTD.**



We need seeds
of Hope to the Future.



Isao Teshirogi, Ph.D.
President and CEO

SHIONOGI Science Program 2014

Shionogi & Co., Ltd. is a Japanese pharmaceutical company which was established in 1879. We have continuously supplied superior pharmaceuticals to people everywhere, based on our company policy to "Constantly strive to provide medicine of the best possible kind essential for protection of the health of the people". Under this basic policy we are making a serious effort to identify good research seeds and to develop them into superior pharmaceuticals. We started an academia and industry collaboration program in Japan in FY2007 for the purpose of leveraging each other's strengths and creating something new together. In the past seven years we have received many applications from Japanese research workers, and we have started a number of joint studies. Also, we launched SHIONOGI Science Program as our global program three years ago. Since then, we have been expanding the target countries each year. This year we are pleased to announce the inclusion of New Zealand. We would like to invite a number of innovative and world-class ideas from you. We hope that together we can create superior pharmaceuticals for those who suffer from diseases all over the world, and to fulfil their unmet medical needs. We are very much looking forward to receiving many novel and inventive ideas from you.

- Application details » Refer to the "SHIONOGI Science Program 2014 Application Guideline" on the SHIONOGI Science Program website.
- Target countries » Australia, Belgium, Denmark, France, Germany, Ireland, Luxembourg, New Zealand, the Netherlands, the UK and Japan.
- Research budgets » Shionogi is planning to adopt a number of projects with budgets of ¥5 million to ¥15 million per year per project.
(Budgets will be determined at the time of contract in accordance with the details of research.)
- Application period » 1:00 am 1st October 2014 - 8:00 am 31st October 2014
(The above date and time are provided in UTC; please check the corresponding date and time in each country in consideration of summer time.)
- Application areas »
1. Novel target molecules for drug discovery to treat obesity or non-alcoholic steatohepatitis (NASH)
 2. Novel target molecules for drug discovery to treat serious bacterial-/fungal-infectious diseases or emerging and re-emerging infectious diseases
 3. Novel target molecules, analytical methods and biomarkers to maximize clinical efficacy of therapeutic cancer peptide vaccines
 4. Novel target molecules for drug discovery to treat cancer
 5. Novel target molecule, analytical methods and promising models for drug discovery to treat psoriasis and/or atopic dermatitis (pruritus)
 6. Ideas for novel technologies and methods for drug discovery to treat central nervous system (CNS) diseases
 7. Ideas for novel biomarkers and target molecules for chronic pain
 8. Ideas for practical biomarker detection technologies for patient segmentation
 9. Ideas for novel next generation therapeutic modalities
 10. Ideas for novel technology of drug formulation
- Inquiries » Make inquiries via the "Inquiries Form" on the website. <http://www.shionogi.co.jp/ssp/>

Application guideline

Target countries	Australia, Belgium, Denmark, France, Germany, Ireland, Luxembourg, New Zealand, the Netherlands, the UK and Japan. Researchers must carry out their research in these targeted eleven countries.	
Selection schedule and application	Primary selection	
	Application period	1:00 am 1st October 2014-8.00 am 31st October 2014 (The above date and time are provided in UTC; please check the corresponding date and time in each country in consideration of summer time.)
	Application method	Apply using the “Application Form”. (Available language is English and Japanese.) Website address: http:// www.shionogi.co.jp/ssp/ Shionogi will inform applicants of receiving application by e-mail within 3 working days. Those applicants who do not receive e-mail, make inquiries via the “Inquiries Form”.
	Announcement of the results of primary selection	Shionogi will inform all applicants of the results by November 30th 2014 in Japan time by e-mail.
	Secondary selection	
	Application period	2months (from December 1st 2014 to January 30th 2015 in Japan time)
	Application method	Shionogi will inform applicants who pass primary selection of the application method. (Research plan, etc.)
	Announcement of successful applicants	Shionogi will inform all applicants of the results of secondary selection by e-mail. (April 25th 2015 in Japan time)
Selection criteria	The selection criteria include: match with the needs of the company; originality of research; rationality; future potential; the possibility of commercialization and conflicts with existing company projects, etc.	
Research period	The research period will be determined at the time of adoption, with a maximum of 5 years as a SHIONOGI Science Program. However, contracts will be renewed each year and the research period may be shortened upon consultation.	
Research budgets	Budgets will be ¥5-15 million per year per project and will be determined at the time of adoption. Budgets are collaboration research budgets.	
Other	Shionogi employees and external advisors (people who have concluded contracts for advisory work with Shionogi) will manage SHIONOGI Science Program 2014 selection process.	
The governing law of SHIONOGI Science Program is the laws of England and Wales.		

Details of recruitment

Novel target molecules for drug discovery to treat obesity or non-alcoholic steatohepatitis (NASH)	Shionogi is searching for ideas for novel target molecules with the exception of transcriptional factors for drug discovery to treat obesity or non-alcoholic steatohepatitis (NASH).
Novel target molecules for drug discovery to treat serious bacterial-/fungal-infectious diseases or emerging and re-emerging infectious diseases	Shionogi is searching for ideas for novel target molecules for drug discovery to treat serious bacterial-/fungal-infectious diseases or emerging and re-emerging infectious diseases
Novel target molecules, analytical methods and biomarkers to maximize clinical efficacy of therapeutic cancer peptide vaccines	Shionogi is searching for ideas for: - adjuvants (immunostimulants) and novel target molecules to augment the efficacy of cancer peptide vaccines. - sensitive and precise analytical methods to monitor the immune status of cancer patients treated with cancer peptide vaccines. - biomarkers to predict the prognosis of cancer patients treated with cancer peptide vaccines.
Novel target molecules for drug discovery to treat cancer	Shionogi is searching for novel target molecules to eradicate cancer cells expressing intrinsic resistance to cancer chemotherapy and immunotherapy.
Novel target molecule, analytical methods and promising models for drug discovery to treat psoriasis and/or atopic dermatitis (pruritus)	<ul style="list-style-type: none"> Shionogi is searching for novel target molecules to regulate Th17 activation, Treg induction and Th1/2 balance. Shionogi is searching for ideas for bridging between human disease and animal models.
Ideas for novel technologies and methods for drug discovery to treat central nervous system (CNS) diseases	Shionogi is searching for ideas for: - novel screening methods to effectively measure synapse functions in the CNS area. - novel drug delivery technologies to cross the blood-brain barrier.
Ideas for novel biomarkers and target molecules for chronic pain	Shionogi is searching for ideas for: - novel biomarkers (functional imaging, mechanistic, or molecular biomarkers) to quantitatively/qualitatively measure/classify/surrogate various indications or patient segments in chronic pain diseases. The biomarkers should be available in both humans and animals. - novel drug target molecules with new mechanisms to treat chronic pain.
Ideas for practical biomarker detection technologies for patient segmentation	Shionogi is interested in novel technologies for the evaluation of biomarker candidates in biological fluids with ultra-sensitivity and good reproducibility. Assay technologies which have a possibility for multiple analyte measurements are more preferable.
Ideas for novel next generation therapeutic modalities	Shionogi is searching for novel ideas for next generation therapeutic modalities, for example, innovative platforms of nucleic acid drugs and antibodies.
Ideas for novel technology of drug formulation	Shionogi is searching for the ideas for novel drug formulation technologies for new drug discovery and life cycle management of existing drugs.